COCP
Cocrystal Pharma, Inc.
There isn't enough reported data to score COCP yet.
COCP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
COCP's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
COCP PE Valuation
COCP has no meaningful PE right now: it lost money over the past year.
COCP Forward outlook
There aren't enough analyst estimates for COCP to show an outlook.
COCP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.75 | +$0.48 |
| Q1 2026 | -$0.72 | +$0.84 |
| Q4 2025 | -$0.78 | +$0.94 |
| Q3 2025 | -$0.93 | +$0.89 |
| Q2 2025 | -$1.23 | +$0.51 |
| Q1 2025 | -$1.56 | +$0.06 |
| Q4 2024 | -$1.72 | +$0.15 |
| Q3 2024 | -$1.82 | +$0.19 |
COCP is still losing money, but far less than before: $0.75 per share over the past year, against $20.16 at its worst in mid-2020.
COCP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2020 | $510K | +27% |
| Q3 2020 | $489K | -0.6% |
COCP's revenue has slid since its 2020 peak: $105,000 last quarter, down 81% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -3032% | N/A |
| Q1 2026 | -1047% | N/A |
| Q4 2020 | -287% | +11634 points |
| Q3 2020 | -554% | -187 points |
| Q2 2020 | -623% | N/A |
| Q1 2020 | -425% | N/A |
| Q4 2019 | -11922% | N/A |
| Q3 2019 | -367% | N/A |
COCP's operating margin was −3032% last quarter, down 2410 points from the same quarter a year ago.
COCP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$1.7M | +$1.4M |
| Q4 2024 | -$3.2M | +$225K |
| Q3 2024 | -$5.1M | -$2.4M |
| Q2 2024 | -$3.7M | +$1.9M |
| Q1 2024 | -$4.5M | -$1.4M |
| Q4 2023 | -$3.4M | +$1.5M |
| Q4 2022 | -$4.9M | -$2M |
| Q4 2021 | -$2.9M | -$548K |
COCP has burned cash in almost every quarter: −$10M over the past year, against −$17M the year before.
COCP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +2K shares |
| 1 year | +36% | +3.6M shares |
| 3 years | +37% | +3.7M shares |
| 5 years | +132% | +7.8M shares |
COCP has 14M diluted shares, up 36% from a year ago.
COCP Net Leverage
COCP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
COCP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.6 | Neutral |
| Stochastic | 36.0 | Neutral |
COCP's weekly RSI is 45 (neutral) and its Stochastic is 36 (neutral).
COCP PE vs Healthcare Sector
COCP has no meaningful PE right now: it lost money over the past year.
COCP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.05 | 5.7% below |
| 20 week MA | $1.06 | 6.6% below |
| 50 week MA | $1.09 | 9.2% below |
| 100 week MA | $1.34 | 26% below |
| 200 week MA | $1.69 | 41% below |
COCP is in a downtrend: it's below all five of its weekly moving averages, and 41% below its 200-week average.
COCP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.40 | $18.6 | +244% |
| 2021 | $18.6 | $8.76 | -53% |
| 2022 | $8.76 | $1.97 | -78% |
| 2023 | $1.97 | $1.72 | -13% |
| 2024 | $1.72 | $3.09 | +80% |
| 2025 | $3.09 | $0.97 | -69% |
| 2026 YTD | $0.97 | $0.99 | +2.1% |
COCP's yearly returns have swung widely, from +244% in 2020 to −78% in 2022. It's up 2.1% so far in 2026.